Conference Focused on the Future of HEOR
New Orleans, LA, USA—May 23, 2019—ISPOR, the professional society for health economics and outcomes research (HEOR), recently concluded its ISPOR 2019 annual conference in New Orleans, LA, USA. The conference convened nearly 4000 healthcare stakeholders representing more than 65 countries and from all sectors of healthcare, including policy makers, global thought leaders, researchers and academicians, public and private payers, healthcare providers, and patient engagement organizations. The conference centered on the timely theme, “Rapid. Disruptive. Innovative. A New Era in HEOR,” and addressed a wide variety of compelling topics in HEOR.
The conference opened with the keynote and first plenary session, “The Dawn of Disruption in the Health Sector: Will Innovative Technologies Require Innovative Thinking?” The keynote was delivered by Daniel Kraft, MD, faculty chair for medicine, Singularity University, founder and chair, Exponential Medicine, Stanford, CA, USA. His keynote explored the impact of disruptive medical therapies on medicine today and into the future, setting the stage for the plenary session. The plenary session panel examined the impact, challenges, and opportunities of the recent renaissance of groundbreaking, new, curative health technologies and included Clifford Goodman, PhD, The Lewin Group, Falls Church, VA, USA who moderated; Timothy Caulfield, LLM, University of Alberta, Edmonton, AB, Canada; Fleur Chandler, Patient Advisory Board, Duchenne, Twickenham, England, UK; Alexander Billioux, MD, PhD, Louisiana Department of Health, Baton Rouge, LA, USA; and Ron Philip, Spark Therapeutics, Inc, Philadelphia, PA, USA. Dr Kraft joined the panel for the question and answer session.
The second plenary, “Medical Device Innovation and Regulation: Turbocharged for Success?” explored ways that regulators can ensure a high level of health protection while also allowing for research and growth in the sector. Panelists included Laurie Burke, MPH, LORA Group LLC and University of Maryland School of Pharmacy, Royal Oak, MD, USA who moderated the session; Stephanie Christopher, MA, Medical Device Innovation Consortium, Arlington, VA, USA; Paul Coplan, ScD, MBA, Johnson and Johnson, New Brunswick, NJ, USA; Stephen A. Hull, MHS, Hull Associates LLC, Rockland, MA, USA; and Harindra Wijeysundera, MD, PhD, Canadian Agency for Drugs and Technologies in Health, Ottawa, ON, Canada.
The third plenary, “Is Healthcare Affordability Driving a Need to Revolutionize Drug Pricing?,” examined the issue of drug pricing in the United States with moderator Colleen M. Flood; University of Ottawa Centre for Health Law, Policy and Ethics; Ottawa, ON, Canada and panelists Muna Bhanji, RPh, Merck, Philadelphia, PA, USA; Meindert Boysen, PharmD, MSc, National Institute for Health and Care Excellence, Manchester, England, UK; Louis P. Garrison, Jr, PhD, University of Washington, Seattle, WA, USA; and Mark Trusheim, MS, NEWDIGS and Massachusetts Institute of Technology, Cambridge, MA, USA.
ISPOR 2019 also hosted a variety of sessions on topics that included, orphan drugs and the challenges they pose to health plans, the future of HEOR, real-world evidence and patient-provided information, how formal health technology assessment could help solve the United States’ high healthcare costs, and patients’ access to biosimilars. ISPOR held its first Annual Awards Banquet to honor the 2019 HEOR Scientific and Leadership Awards winners. The Society’s journal, Value in Health released its 20th anniversary issue featuring the publication’s new “look” and held a special spotlight session at the conference with the founding and current editors-in-chief taking a retrospective look at the journal. And ISPOR’s Women in HEOR initiative held a session on mentorship and thought leadership at the conference.
ISPOR CEO and Executive Director Nancy S. Berg stated, “Our ISPOR 2019 annual conference convened HEOR leaders from around the world to discuss the new emerging era in health economics and outcomes research and to reimagine HEOR. The focus on disruption and innovation in the field will help shape the future of HEOR and aligns with the Society’s mission to improve healthcare decisions.”
ISPOR is recognized globally as the leading professional society for health economics and outcomes research and its role in improving healthcare decisions. ISPOR 2019 is the leading global HEOR conference and draws nearly 4000 healthcare thought leaders and stakeholders, including researchers and academicians, assessors and regulators, payers and policy makers, the life sciences industry, healthcare providers, and patient engagement organizations.
ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field.
Web: www.ispor.org | LinkedIn: www.linkedin.com/company/ispororg | Twitter: www.twitter.com/ispororg (@ISPORorg) | YouTube: www.youtube.com/ispororg | Facebook: www.facebook.com/ispororg | Instagram: www.instagram.com/ispororg